LeonaBio Reports First Quarter 2026 Financial Results and Provides Business UpdateAdvancing Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator, a Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations
LeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B. Silverman, J.D.Seasoned leaders bring deep experience in oncology and neurology drug development, corporate strategy, operational execution, and capital markets as company continues to advance clinical pipeline
Independent Nonclinical Research on Lasofoxifene Presented at American Association for Cancer Research Annual Meeting 2026 Consistent with LeonaBio’s DataResults showed lasofoxifene protected against hormone withdrawal-induced bone loss and maintained a robust anti-tumor response in primary and metastatic animal models of ER+ breast cancer
LeonaBio Reports Full Year 2025 Financial Results and Provides Business UpdateAcquired License to Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator (SERM), a Potential Multi-Billion Dollar Opportunity as Treatment Option for Breast Cancer Patients with ESR1-Mutations
LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business OfficerBrings more than 25 years of biopharma business development and corporate strategy expertise
